LDHAL6B

Across TCGA pan-cancer cohorts, LDHAL6B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LDHAL6B data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LDHAL6B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LDHAL6B expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC are the cancer types where LDHAL6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.519	.015	10	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LDHAL6B–CCRCC (DFS)

Open the CCRCC breakdown →